Global languages
2022-07-20
Regulatory

Best quarter yet. Sales reaching all-time high

April 1-June 30, 2022

  • Net sales increased by 36% to SEK 184 million (135).
  • Sales increased organically by 28% (23), currency effect 8%.
  • EBITDA increased to SEK 61 million (47).
  • EBITDA margin amounted to 33% (35).
  • Profit before tax increased to SEK 47 million (39).
  • Earnings per share before and after dilution increased to SEK 1.56 (1.30).
  • Cash flow from operating activities increased to SEK 40 million (39).


January 1-June 30, 2022

  • Net sales increased by 28% to SEK 346 million (269).
  • Sales increased organically by 21% (16), currency effect 7%.
  • EBITDA increased to SEK 121 million (93).
  • EBITDA margin amounted to 35% (35).
  • Profit before tax increased to SEK 95 million (75).
  • Earnings per share before and after dilution increased to SEK 3.17 (2.49).
  • Cash flow from operating activities increased to SEK 78 million (65).

Contact

Adele Horn
Corporate Communications & Investor Relations
Direct: + 46 46 460 26 04
Mobile: + 46 72 206 50 88
www.cellavision.com
adele.horn@cellavision.com

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 17 local market support organizations covering more than 40 countries. In 2021, sales were SEK 566 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-07-20 07:20 CEST.

Attachments

CellaVision Interim Report Q2 2022

Share